6 completed, 1 terminated. 7 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 6, Terminated 1 |
Follow Gastrinoma: new trials by email Literature Review of Gastrinoma trials Research Report on Gastrinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors everolimus, vatalanib, pharmacological study - Gastrinoma, Glucagonoma | Phase 1 | Completed | Mayo Clinic | 96 | 2004-12-01 | 2024-08-21 |
| Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors 90Y-DOTA-tyr3-OCTREOTIDE - Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor | Phase 1 | Completed | O'Dorisio, M S | 27 | 2002-01-01 | 2016-06-21 |
| Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer trastuzumab, tipifarnib - Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2000-06-01 | 2013-02-11 |
| Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum floxuridine, leucovorin calcium, oxaliplatin - Cancer | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 2000-04-01 | 2011-04-26 | |
| Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu recombinant interleukin-12, ABI-007/carboplatin/trastuzumab - Advanced Adult Primary Liver Cancer, Anaplastic Thyroid Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 15 | 1999-08-01 | 2013-02-28 |
| Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer yttrium Y 90-edotreotide - Brain and Central Nervous System Tumors, Breast Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 60 | 1998-01-01 | 2013-05-01 |
| Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer indium In 111 pentetreotide - Brain and Central Nervous System Tumors, Childhood Langerhans Cell Histiocytosis | Phase 1 | Terminated | Yale University | 35 | 1996-10-01 | 2014-07-02 |
Carcinoma, Islet Cell (7) · Insulinoma (7) · Glucagonoma (6) · Somatostatinoma (6) · Vipoma (5) · Carcinoma, Medullary (4) · Carcinoma, Non-Small-Cell Lung (4) · Carcinoma, Renal Cell (4) · Neoplasms (4) · Pheochromocytoma (4) · Adenoma, Islet Cell (3) · Appendiceal Neoplasms (3) · Bile Duct Neoplasms (3) · Breast Neoplasms (3)
Adenocarcinoma (7) · Adenoma (7) · Carcinoma (7) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Endocrine Gland Neoplasms (7) · Endocrine System Diseases (7) · Neoplasms by Histologic Type (7) · Neoplasms by Site (7) · Neoplasms, Germ Cell and Embryonal (7) · Neoplasms, Glandular and Epithelial (7) · Neoplasms, Nerve Tissue (7) · Neuroectodermal Tumors (7) · Neuroendocrine Tumors (7) · Pancreatic Diseases (7)
Trastuzumab (2) · 90Y-octreotide, DOTA-Tyr(3)- (1) · Everolimus (1) · Floxuridine (1) · High-Energy Shock Waves (1) · Interleukin-12 (1) · Interleukin-12 Subunit p35 (1) · Leucovorin (1) · Oxaliplatin (1) · pentetreotide (1) · tipifarnib (1) · vatalanib (1)
National Cancer Institute (NCI) (2) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · Novartis Pharmaceuticals (1) · O'Dorisio, M S (1) · Yale University (1)
United States (7)
Anthony W. Tolcher, MD (1) · John R. Murren, MD (1) · Julian R. Molina, M.D., Ph.D. (1) · Larry K. Kvols, MD (1) · Leonard B. Saltz, MD (1) · M. Sue O'Dorisio, MD, PhD (1) · William Carson (1)
U01CA076576 (1)